Kura Oncology (KURA): Positive Phase II Data on tipifarnib - Oppenheimer

August 11, 2016 8:14 AM EDT
Get Alerts KURA Hot Sheet
Price: $6.30 +4.13%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade KURA Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer analyst, Michelle Gibson, reiterated her Outperform rating on shares of Kura Oncology (NASDAQ: KURA) after the company announced positive topline results from a Phase 2 study of tipifarnib in advanced HRAS-mutant solid tumors. In the cohort comprising patients with non-hematologic malignancies other than thyroid cancer (n=11), two PRs were observed, both in patients with head and neck squamous cell carcinomas ("H&N", n=3). Kura will now begin enrolling an additional seven patients into the cohort, per trial protocol.

The analyst stated "We view this data as validating Kura's HRAS hypothesis for tipifarnib as a single-agent to inhibit HRAS-mediated MAPK-activation. Follow-up data is expected in 2017 (potentially ASCO), and we will be looking for further clarity on HRAS' role in these tumors, including as a driver-oncogene. We note, however, that tipifarnib's mechanism in HRAS is distinct from other indications (CMML, PTCL, MDS) being evaluated".

No change to the price target of $16.00

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $4.36 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment